Joseph Glorioso, III, MD, PhD: Turning Bad Guys into Good Guys

Years Funded: 2018-2020

Antigenic Stealthing of oHSV for Systemic Treatment of Melanoma
At the University of Pittsburgh (Pittsburgh, PA), Joseph Glorioso, III, MD, PhD, is pioneering creative new strategies to more safely and successfully target and triumph over melanoma and other metastatic cancers. His studies build on past successes in fighting solid tumors with viruses and a patient’s own immune system.

Read More
Brent Hanks, MD, PhD: Feeling optimistic

Years Funded: 2016-2019

Metabolic Reprogramming of Dendritic Cell-Based Cancer Vaccines
At Duke University School of Medicine (Durham, NC), tumor immunologist Brent Hanks, MD, PhD, is pioneering a new strategy to engineer dendritic cells to successfully resist cancer’s efforts to stop them from triggering a body’s own anti-cancer immune response.

Read More
Meenakshi Hegde, MD: Tandem CAR T Cells Do Double Duty

Years Funded: 2015-2018

Adoptive Cellular Therapy for Melanoma
An innovative, bispecific approach to CAR T-cell engineering is being explored by Meenakshi Hegde, MD, at the Baylor College of Medicine Center for Cell and Gene Therapy (Houston, TX). Designed to expand the reach and impact of traditional approaches to CAR T-cell therapies, Dr. Hegde is developing tandem CAR T cells that can recognize and destroy more than one cancer biomarker at a time.

Read More

Join the Alliance

  • This field is for validation purposes and should be left unchanged.